Co-investigators: Craig Woods DVM, MS, MBA and Chad VanDenBerg Pharm.D., MS.
Summary: This is a prospective clinical study in dogs to evaluate the ability of a tumor imaging agent to fluoresce during surgery.
General Study Procedures: Patients qualifying for the study will be administered the imaging agent, via intravenous injection, 72 to 24 hours before surgery. During surgery, the tumor will be imaged using a special near-infrared camera. After surgical removal, a portion of the tumor will be used for further histological and quantitative analysis.
General Eligibility: Dogs with non-hepatic solid tumors that are scheduled for surgical resection. Other inclusion/exclusion will be discussed during owner consenting process.
The study related procedures are at no cost to dog owners. If enrolled, dog owners will be credited $200 towards their surgery.